Gate News message, April 15 — Amazon Web Services (AWS) has launched Amazon Bio Discovery, an AI application designed for early-stage drug discovery. The platform enables scientists to run computational workflows without coding and send shortlisted molecules to lab partners for synthesis and testing.
The product combines biological foundation models that generate and evaluate drug molecules with an AI agent that assists users in selecting models, setting parameters, and interpreting results. Early adopters include Bayer, the Broad Institute, and Voyager Therapeutics. AWS Vice President for Healthcare AI and Life Sciences Rajiv Chopra stated that work previously requiring 18 months to produce 300 potential drug candidates can now be completed in a couple of weeks.
The service will begin with a free trial offering five experimental units before transitioning to subscription-based pricing tiers.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
Related Articles
Naver and Kakao Expected to Report Strong Q1 Results as AI Investments Continue
Naver and Kakao are expected to report strong Q1 2026 earnings driven by commerce and advertising, despite limited impact from early-stage AI products. Both companies are significantly investing in AI infrastructure and shifting strategies to integrate AI into existing services.
GateNews4m ago
Anthropic Releases Claude Opus 4.7 With Weakened Cyber Capabilities
Anthropic released an upgraded version of its flagship model, Claude Opus 4.7, on April 16 (local time). Compared to the previous Opus 4.6 model, Opus 4.7 demonstrates "significant improvements" in advanced software engineering capabilities, particularly on difficult tasks, with enhanced rigor and c
CryptoFrontier10m ago
xAI to Provide Massive GPU Computing Power to Cursor for AI Code Model Training
Elon Musk's xAI will provide computing power to programming startup Cursor, utilizing thousands of GPUs to train its new code model. This shift enhances xAI’s role in computing services, potentially increasing revenue and addressing operational costs amid ongoing losses.
GateNews11m ago
Anthropic Partners with TrendAI to Integrate Claude Models into Enterprise AI Security Platform
TrendAI has partnered with Anthropic to integrate Claude models into its platform, enhancing threat research and AI security operations. This collaboration aims to identify vulnerabilities before production, reflecting the industry's shift toward AI security.
GateNews34m ago
OpenAI Agrees to Pay Over $20 Billion for Cerebras Chips Over Three Years, Receives Equity Stake
OpenAI has agreed to purchase over $20 billion in AI chips from Cerebras over three years, securing an equity stake in the company, aiming to lower computational costs as it expands its AI services.
GateNews34m ago
UK AI Minister Criticizes OpenAI for Pausing Stargate Data Center Project
Britain's AI minister criticized OpenAI's decision to pause its UK data center project, linking it to financing issues rather than energy prices. Microsoft is set to lease capacity at another site, impacting the UK's AI investment goals.
GateNews44m ago
